Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Revised 2011:2.
   Google Scholar
• Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. EurRespir J 2006;27:397–412.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398–401.
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. EurRespir J Suppl 2003;41:46–53.
   PubMed Web of Science ®Google Scholar
• Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. EurRespir J 2007;29:1224–38.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, Revised 2011:15–6.
   Google Scholar
• Hurst JR 1st, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Eng J Med 2010;363:1128–38.
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581–6.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434–40.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–80.
   PubMed Web of Science ®Google Scholar
• Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92:664–7.
   PubMed Web of Science ®Google Scholar
• Buess T, Ludwig C. Diagnostic value of C-reactive protein in comparison with erythrocyte sedimentation as routine admission diagnostic test. Schweiz Med Wochenschr 1995; 125:120–4.
   PubMedGoogle Scholar
• Saldías PF, Díaz PO, Dreyse DJ, Gaggero BA, Sandoval AC, Lisboa BC. Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations. Rev Med Chil 2012;140:10–8.
   PubMed Web of Science ®Google Scholar
• Bulut I, Arbak P, Coskun A, Balbay O, Annakkaya AN, Yavuz O, Gülcan E. Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease. Med Princ Pract 2009;18:289–93.
   PubMed Web of Science ®Google Scholar
• Hillas G, Moschos C, Dimakou K, Vlastos F, Avgeropoulou S, Christakopoulou I, Rasidakis A, Bakakos P. Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients. Scand J Clin Lab Invest 2008;68:542–7.
   PubMed Web of Science ®Google Scholar
• Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcinoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis 1995;50:177–82.
   PubMedGoogle Scholar
• Karnak D, Beder S, Kayacan O, Ibiş E, Oflaz G. Neuron-specific enolase and lung cancer. Am J ClinOncol 2005;28:586–90.
   Web of Science ®Google Scholar
• Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest 1996;109: 995–1000.
   PubMed Web of Science ®Google Scholar
• Marechal F, Berthiot G, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcinoembryonic antigen in non-neoplastic diseases of the lung. Anticancer Res 1988;8:677–80.
   PubMed Web of Science ®Google Scholar
• Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, Kosuge T. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2012;19:636–41
   PubMed Web of Science ®Google Scholar
• Sorensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58:A4331.
   Google Scholar
• Vignot S, Brochet C, Debord C, Lauratet B, Bernard M. Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer. Ann BiolClin 2011;69:597–604.
   Google Scholar
• Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1996;104:66–73.
   Google Scholar
• Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003;68:1075–82.
   PubMed Web of Science ®Google Scholar
• Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005;7:840–3.
   PubMed Web of Science ®Google Scholar
• Shitrit D, Zingerman B, Shitrit AB, Shiomi D, Kramer MR. Diagnostic value of CYFRA21-1, CEA, CA19-9, CA15-3, and CA125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005;10:501–7.
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Endo K, Kawamura Y, Yoshida T, Saga T, Watanabe Y, Koizumi M, Nakashima T, Konishi J, Yamaguchi N, Yatani R. Normal bronchial mucus contains high levels of cancer-associated antigens, CA125, CA19-9, and carcinoembryonic antigen. Cancer 1990;653:506–10.
   Google Scholar
• Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation malignant and nonmalignant diseases. Gynecol Oncol 2002;85:175–8.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Zorlu A, Dogan OT, Karahan O, Tandogan I, Akkurt I. Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease. Clin Cardiol 2011;34:244–8.
   PubMed Web of Science ®Google Scholar
• Rusanov V, Kramer MR, Raviv Y, Medalion B, Guber A, Shitrit D. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest 2012;141:1047–54.
   PubMed Web of Science ®Google Scholar
• Kim ES, Park KU, Song J, Lim HJ, Cho YJ, Yoon H, Lee J, Lee CT, Park JS. The clinical significance of CA-125 in pulmonary tuberculosis. Tuberculosis 2013;93:222–6.
   PubMed Web of Science ®Google Scholar
• Gronowitz E, Pitkänen S, Kjellmer I, Heikinheimo M, Strandvik B. Association between serum oncofetal antigens CA19-9 and CA125 and clinical status in patients with cystic fibrosis. Acta Paediatr 2003;92:1267–71.
   PubMed Web of Science ®Google Scholar
• Marinaş AE, Ciurea P, Pirici D, Ciurea R. Chronic bronchitis: a retrospective clinicopathologic study of 25 cases. Rom J Morphol Embryol 2012;53:503–13.
   PubMed Web of Science ®Google Scholar
• Rottenberg Y, Nisman B, Peretz T. Extreme high levels of CA19.9 associated with adenocarcinoma of the lung. Israel Med Assoc J. 2009;11:116–7.
   PubMed Web of Science ®Google Scholar
• Shin JY, Yoo SJ, Park BM, Jung SS, Kim JO, Lee JE. Extremely increased serum carbohydrate antigen 19-9 levels caused by new or resistant infections to previous antibiotics in chronic lung diseases. Tuberc Respir Dis 2013;75: 125–7.
   PubMedGoogle Scholar
• Noguchi T, Yamamoto K, Moriyama G, Saito Y, Kyoyama H, Mikami S, Ono R, Kobayashi T, Yamana K, Evaluation of serum levels of carcinoembryonic antigen in allergic bronchopulmonary aspergillosis. Nippon Med Sch 2013;80: 404–9.
   PubMed Web of Science ®Google Scholar
• Beaudonnet A, Gounon G, Pichot J, Revenant MC. Sex- and age-related influences on carcinoembryonic antigen in blood. ClinChem 1981;27:771.
   Google Scholar
• Touitou Y, Proust J, Klinger E, Nakache JP, Huard D, Sachet A. Cumulative effects of age and pathology on plasma carcinoembryonic antigen in an unselected elderly population. Eur J Cancer ClinOncol 1984;20:369–74.
   PubMedGoogle Scholar
• Stevens DP, Mackay IR. Increased carcinoembryonic antigens in heavy smokers. Lancet 1973;ii:1238–9.
   Google Scholar
• Ferrigno D1, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J 1994;7:186–97.
   PubMed Web of Science ®Google Scholar
• Wang R, Wang G, Zhang N, Li X, Liu Y. Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer. Biomed Res Int 2013;2013:195692.
   PubMedGoogle Scholar
• Collazos J, Esteban C, Fernández A, Genollá J. Measurement of the serum tumor marker neuron specific enolase in patients with benign pulmonary diseases. Am J Respir Crit Care Med 1994;150:143–5.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, Sekizawa K. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 2003;123:2001–6.
   PubMed Web of Science ®Google Scholar
• Arai T, Inoue Y, Sugimoto C, Inoue Y, Nakao K, Takeuchi N, Matsumuro A, Hirose M, Nakata K, Hayashi S. CYFRA21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. Respirology 2014:19:246–52.
   PubMed Web of Science ®Google Scholar